Servier has re-submitted an application to the Pharmaceutical Benefits Advisory Committee (PBAC) for the consideration of vorasidenib for reimbursement.
To share your valuable experience and insights, the consultation hub is available at https://ohta-consultations.health.gov.au/pbac/ and will close for comments on 21st January 2026.
© 2026 SERVIER. All Rights Reserved
This site and included information is intended for residents of Australia. Servier Australia acknowledges First Nations peoples and communities as the Traditional Owners of the land. We acknowledge and pay our respects to Elders past and present, and emerging leaders. 105038VORA242WEBS
To report a side effect for VORANIGO® (vorasidenib) or a Servier product, please contact us
